Swedbank AB Purchases New Shares in Repligen Corporation $RGEN

Swedbank AB purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 25,300 shares of the biotechnology company’s stock, valued at approximately $4,146,000.

Other hedge funds also recently bought and sold shares of the company. Bayforest Capital Ltd purchased a new stake in Repligen during the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC purchased a new stake in Repligen during the fourth quarter valued at $33,000. Measured Wealth Private Client Group LLC purchased a new stake in Repligen during the third quarter valued at $29,000. Farther Finance Advisors LLC raised its stake in Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new stake in Repligen during the third quarter valued at $65,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RGEN. Barclays upped their price target on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. HC Wainwright upped their price target on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Wells Fargo & Company decreased their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $166.15.

Repligen Trading Up 0.1%

Shares of RGEN opened at $115.19 on Wednesday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a market cap of $6.50 billion, a P/E ratio of 127.99, a P/E/G ratio of 2.22 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The company’s fifty day simple moving average is $117.78 and its 200-day simple moving average is $140.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million for the quarter, compared to the consensus estimate of $192.05 million. During the same quarter in the prior year, the firm posted $0.39 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.